Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to discuss a collaboration with Moffitt Cancer Center the number one cancer hospital in Florida and the Southeast USA.
In this insightful interview, Dr Allan Syms, Executive Chairman of Cizzle Biotechnology, shares key updates on the company’s latest collaboration with Moffitt Cancer Centre, a renowned institution in lung cancer treatment. He discusses the strategic significance of this partnership and the role of the CIZ1B biomarker in improving early detection of lung cancer. Dr Syms also addresses the potential impact of the biomarker on existing screening methods, the competitive landscape, and the future outlook for Cizzle Biotechnology. This conversation highlights the company’s transition from research and development to market application, offering a glimpse into its promising future.
Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.